Bozz,
Yes it is lots of $$$....and Sarepta's exon skipping drugs only serve 20% of the DMD population in the USA.
Greenfield market - and ANP will have ODD protection of 7 to 10 years exclusivity.
Sarepta is the most logical partner:
- They have PPMD on side
- They have Janet from FDA on side
- Clinical relationships throughout the US
- Extensive patient database
- Logistical footprint in the US for fast GoToMarket once FDA approves
- BIG investors on their register who will back them (Fidelity etc)
- THEY HAVE MOST TO LOSE....because their GT program is stuffed!
.
Where others have failed will Atl1102 succeed ?, page-630
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.004(5.88%) |
Mkt cap ! $64.91M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 7.2¢ | 6.9¢ | $91.71K | 1.319M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 7.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 18695 | 1 |
View Market Depth
| Last trade - 16.10pm 29/04/2024 (20 minute delay) ? |
|
|||||
|
Last
7.1¢ |
Change
0.004 ( 3.20 %) |
||||
| Open | High | Low | Volume | ||
| 6.9¢ | 7.2¢ | 6.9¢ | 129842 | ||
| Last updated 15.32pm 29/04/2024 ? | |||||
| PER (ASX) Chart |